Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.

Other equities research analysts have also issued reports about the company. Dawson James reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Tonix Pharmaceuticals in a research note on Wednesday, August 23rd. Drexel Hamilton initiated coverage on Tonix Pharmaceuticals in a research report on Tuesday, August 22nd. They set a “buy” rating on the stock. Finally, Roth Capital raised Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Friday, August 18th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) opened at $4.05 on Friday. Tonix Pharmaceuticals has a one year low of $2.85 and a one year high of $9.40.

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 184,377 shares of the company’s stock after purchasing an additional 41,264 shares during the period. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.51% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/02/tonix-pharmaceuticals-tnxp-rating-lowered-to-strong-sell-at-valuengine.html.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.